Lytix Biopharma ASSTU:6BG -2.20%22 Quick Ratio is 9.50 as of Mar. 2026, which is 62% above its 10-year median of 5.85. GuruFocus rates STU:6BG with a GF Score™ of 22/100 and a GF Value™ of €0.01. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Lytix Biopharma AS ranks better than 77.04% on this metric.
Lytix Biopharma AS has a quick ratio of 9.50. It generally indicates good short-term financial strength.
The historical rank and industry rank for Lytix Biopharma AS's Quick Ratio or its related term are showing as below:
STU:6BG'
s Quick Ratio Range Over the Past 10 Years
Min: 2.56 Med: 5.85 Max: 24.26
Current: 9.5
During the past 8 years, Lytix Biopharma AS's highest Quick Ratio was 24.26. The lowest was 2.56. And the median was 5.85.
STU:6BG's Quick Ratio is ranked better than 77.04% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs STU:6BG: 9.50
Lytix Biopharma AS (STU:6BG) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Lytix Biopharma AS Quick Ratio Related Terms
Lytix Biopharma AS Quick Ratio Historical Data
* Premium members only.
The historical data trend for Lytix Biopharma AS's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6BG vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Lytix Biopharma AS's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lytix Biopharma AS Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lytix Biopharma AS's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Lytix Biopharma AS's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Lytix Biopharma AS's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lytix Biopharma AS (STU:6BG) has a Quick Ratio of 9.50 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lytix Biopharma AS and its competitors. This is 62% above median its historical median of 5.85. Over the past decade, Lytix Biopharma AS's Quick Ratio has ranged from 2.56 to 24.26. According to the industry distribution chart, Lytix Biopharma AS ranks #324 out of 1411 companies in the Biotechnology industry, placing it in the top 23%.
Is Lytix Biopharma AS's Quick Ratio too high?
Lytix Biopharma AS's current Quick Ratio of 9.50 is 62% above median its 10-year median of 5.85. Over the past 10 years, this metric has ranged from a low of 2.56 to a high of 24.26. The Biotechnology industry median Quick Ratio is 3.59. Lytix Biopharma AS's value of 9.50 is 164.6% above this industry median. Based on the distribution chart, Lytix Biopharma AS ranks #324 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lytix Biopharma AS has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lytix Biopharma AS ranks #324 out of 1411 companies for Quick Ratio. This places Lytix Biopharma AS in the top 23% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.59. Lytix Biopharma AS's value of 9.50 is 164.6% above this benchmark. Historically, Lytix Biopharma AS's own Quick Ratio has ranged from 2.56 to 24.26 over the past decade. While the company's 10-year median is 5.85 vs. the industry median of 3.59, Lytix Biopharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lytix Biopharma AS's current Quick Ratio of 9.50 is 164.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lytix Biopharma AS and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lytix Biopharma AS's current Quick Ratio is 9.50, which is 62% above median its own 10-year median of 5.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Lytix Biopharma AS (STU:6BG) has a current Quick Ratio of 9.50. The stock's GF Value™ is €0.01, compared to a current price of €0.80 — trading 7920% above its estimated fair value. The current Quick Ratio is 9.50, which is 62% above median its 10-year median of 5.85 and 164.6% above the Biotechnology industry median of 3.59. Lytix Biopharma AS's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Lytix Biopharma AS (STU:6BG), the current Quick Ratio is 9.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lytix Biopharma AS (STU:6BG) Overvalued in 2026?
Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued.
The current stock price of €0.80 is trading 7920% above its estimated GF Value™ of €0.01.
Key valuation signals for STU:6BG:
Quick Ratio: 9.50 (62% above median its 10-year median of 5.85)
GF Value™: €0.01 vs. price of €0.80 (7920% above fair value)
Industry Position: 164.6% above the Biotechnology median (#324 of 1411)
No single metric tells the full story. See the STU:6BG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
22GF Score
Get the complete analysis for STU:6BG
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6BG has been successfully added to your 
